[1] |
夏云龙, 张运. 萌芽中的肿瘤心脏病学: 机遇与挑战[J]. 中华心血管病杂志, 2017(3): 182-185.
|
|
XIA Y L, ZHANG Y. Oncocardiology in the bud: opportunities and challenges[J]. Chin J Cardiol, 2017(3): 182-185.
|
[2] |
DE BOER R A, MEIJERS W C, VAN DER MEER P, et al. Cancer and heart disease: associations and relations[J]. Eur J Heart Fail, 2019, 21(12): 1515-1525.
doi: 10.1002/ejhf.1539
pmid: 31321851
|
[3] |
陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253.
|
|
CHEN Y, CHEN C M, LIU Z Y, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Stud Sci Sci, 2015, 33(2): 242-253.
|
[4] |
刘斌亮, 王延风, 马飞. 从肿瘤学出发, 浅谈肿瘤心脏病学的发展、现状与挑战[J]. 中国心血管杂志, 2018, 23(5): 357-359.
|
|
LIU B L, WANG Y F, MA F. Starting from the oncology, analyze the development, situation and challenges of Cardio-Oncology[J]. Chin J Cardiovasc Med, 2018, 23(5): 357-359.
|
[5] |
ZHANG Y, LIU Y, XIA Y. Dedicated to cardio-oncology[J]. Eur Heart J, 2020, 41(8): 907-909.
doi: 10.1093/eurheartj/ehaa064
pmid: 32080730
|
[6] |
KY B. JACC: CardioOncology: poised to serve a maturing, collaborative field[J]. JACC CardioOncol, 2019, 1(1): 131-132.
doi: 10.1016/j.jaccao.2019.06.001
|
[7] |
LIU Y, ZHANG Y L, LIU J W, et al. Emergence, development, and future of cardio-oncology in China[J]. Chin Med J (Engl), 2018, 131(21): 2640-2644.
|
[8] |
ZHANG Y H, ZHANG Z R, LIU Y, et al. Cardio-oncology in China: we are on the go![J]. JACC CardioOncol, 2020, 2(1): 139-143.
doi: 10.1016/j.jaccao.2020.02.007
|
[9] |
ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801.
doi: 10.1093/eurheartj/ehw211
|
[10] |
ARMENIAN S H, LACCHETTI C, BARAC A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(8): 893-911.
doi: 10.1200/JCO.2016.70.5400
pmid: 27918725
|
[11] |
PLANA J C, GALDERISI M, BARAC A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. J Am Soc Echocardiogr, 2014, 27(9): 911-939.
doi: 10.1016/j.echo.2014.07.012
|
[12] |
CARDINALE D, COLOMBO A, BACCHIANI G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation, 2015, 131(22): 1981-1988.
doi: 10.1161/CIRCULATIONAHA.114.013777
pmid: 25948538
|
[13] |
JOHNSON D B, BALKO J M, COMPTON M L, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755.
doi: 10.1056/NEJMoa1609214
|
[14] |
GULATI G, HECK S L, REE A H, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol[J]. Eur Heart J, 2016, 37(21): 1671-1680.
doi: 10.1093/eurheartj/ehw022
pmid: 26903532
|
[15] |
THAVENDIRANATHAN P, POULIN F, LIM K D, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review[J]. J Am Coll Cardiol, 2014, 63(25): 2751-2768.
doi: 10.1016/j.jacc.2014.01.073
|
[16] |
ZHANG S, LIU X B, BAWA-KHALFE T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11): 1639-1642.
doi: 10.1038/nm.2919
pmid: 23104132
|
[17] |
SAWAYA H, SEBAG I A, PLANA J C, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab[J]. Circ Cardiovasc Imaging, 2012, 5(5): 596-603.
doi: 10.1161/CIRCIMAGING.112.973321
pmid: 22744937
|
[18] |
CURIGLIANO G, LENIHAN D, FRADLEY M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations[J]. Ann Oncol, 2020, 31(2): 171-190.
doi: S0923-7534(19)36080-6
pmid: 31959335
|
[19] |
LYON A R, YOUSAF N, BATTISTI N M L, et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol, 2018, 19(9): e447-e458.
doi: 10.1016/S1470-2045(18)30457-1
|
[20] |
中国抗癌协会整合肿瘤心脏病学分会中华医学会心血管病学分会肿瘤心脏病学学组中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 等. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038.
|
|
Society of Integrative Cardio-Oncology China Anti-Cancer Association, the Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardiovascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Doctor Association, et al. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)[J]. Chin J Clin Oncol, 2020, 47(20): 1027-1038.
|
[21] |
马军, 秦叔逵, 沈志祥. 蒽环类药物心脏毒性防治指南(2013年版)[J]. 临床肿瘤学杂志, 2013, 18(10): 925-934.
|
|
MA J, QIN S K, SHEN Z X. Guidelines for the prevention and treatment of cardiotoxicity of anthracycline drugs (2013 edition)[J]. Chin Clin Oncol, 2013, 18(10): 925-934.
|
[22] |
李艳阳, 王云姣, 韩德军, 等. 基于数据挖掘的中医药治疗抗肿瘤药物心脏毒性用药规律研究[J]. 中国中医基础医学杂志, 2022, 28(1): 138-141.
|
|
LI Y Y, WANG Y J, HAN D J, et al. Research on medication rule of cardiotoxicity with traditional Chinese medicine based on data mining[J]. J Basic Chin Med, 2022, 28(1): 138-141.
|
[23] |
薛静娴, 卞卫和, 姚昶. 中药汤剂治疗乳腺癌患者蒽环类药物化疗心脏毒性的meta分析[J]. 世界科学技术-中医药现代化, 2018, 20(6): 922-928.
|
|
XUE J X, BIAN W H, YAO C. Meta-analysis of curative effects of traditional Chinese herbal decoction on breast carcinoma patients in doxorubicin-induced cardiotoxicity[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2018, 20(6): 922-928.
|
[24] |
BROWN S A. Preventive cardio-oncology: the time has come[J]. Front Cardiovasc Med, 2019, 6: 187.
doi: 10.3389/fcvm.2019.00187
|
[25] |
LYON A R, DENT S, STANWAY S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society[J]. Eur J Heart Fail, 2020, 22(11): 1945-1960.
doi: 10.1002/ejhf.1920
|
[26] |
LYON A R, LÓPEZ-FERNÁNDEZ T, COUCH L S, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2022.
|
[27] |
PLANA J C, THAVENDIRANATHAN P, BUCCIARELLI-DUCCI C, et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient[J]. JACC Cardiovasc Imaging, 2018, 11(8): 1173-1186.
doi: 10.1016/j.jcmg.2018.06.003
|
[28] |
ARMSTRONG G T, KAWASHIMA T, LEISENRING W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study[J]. J Clin Oncol, 2014, 32(12): 1218-1227.
doi: 10.1200/JCO.2013.51.1055
pmid: 24638000
|